U.S. markets closed

AzurRx BioPharma, Inc. (AZRX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
0.7797+0.0601 (+8.35%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
MACD

MACD

Previous Close0.7196
Open0.7198
Bid0.7520 x 1800
Ask0.7789 x 3200
Day's Range0.7000 - 0.7798
52 Week Range0.6500 - 2.6300
Volume794,312
Avg. Volume3,884,609
Market Cap58.04M
Beta (5Y Monthly)1.52
PE Ratio (TTM)N/A
EPS (TTM)-1.4680
Earnings DateAug 13, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.50
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • FMW Media, Inc.’s “New to The Street” TV Announces 8 Interviews Being Broadcast on NEWSMAX TV, Sunday, May 16, 2021, Hour Slot 10-11AM ET.
    GlobeNewswire

    FMW Media, Inc.’s “New to The Street” TV Announces 8 Interviews Being Broadcast on NEWSMAX TV, Sunday, May 16, 2021, Hour Slot 10-11AM ET.

    NEW YORK, May 14, 2021 (GLOBE NEWSWIRE) -- FMW Media’s “New to The Street” TV broadcasting its national syndicated 1- hour show, Sunday, May 16, 2021 on NEWSMAX TV from 10-11AM ET. “New To The Street’s” “BIG” TV Sunday line-up features the following Companies and their businesses representatives: 1) American Premium Water (OTC: HIPH) with Ryan Fishoff, CEO 2) Winners Inc. (OTC: WNRS) and its Subsidiary, VegasWINNER, Inc., with Wayne Allyn Root, CEO 3) Innerscope Hearing Technologies, Inc. (OTC:INND) with CEO Matthew Moore 4) ZK International, Inc’s (NASDAQ: ZKIN) blockchain technology subsidiary “xSigma” ($SIG) with Alex Lebed, CTO 5) AzurRx BioPharma, Inc. (NASDAQ: AZRX) with James Sapirstein, Chairman & CEO 6) Simplicity Esports and Gaming, Inc. (OTCQB:WINR) with Roman Franklin, President & CEO 7) PayPolitan with Nile Tharandts Ortiz, CEO & Co-founder 8) PetProducts.com with Allen Simon, CEO American Premium Water (OTC: HIPH) CEO, Ryan Fishoff talks to “New To The Street” TV about their business, their brands, and their plans to grow the Company into a market leader in the CBD consumer products space. Broadcast: NEWSMAX TV. The show interviews Mr. Wayne Allyn Root, CEO of Winners, Inc.’s (OTC: WNRS) subsidiary, VegasWINNERS, Inc. Appearing monthly on “New To The Street, Wayne talks about sports betting, giving advice, and sharing content from VegasWINNER, Inc.’s newly launched show, KRUSH House. Matthew Moore, CEO of InnerScope Hearing Technologies, Inc.’s (OTC:INND), interview with “New To The Street talks about the Company’s emerging and disruptive leadership in the “Direct-to-Consumer Hearing Technology” space. And, a further discussion about their recent launch of the Self-Adjusting Hearing Aids app. The show continues its broadcast with Mr. Alex Lebed, the Chief Technology Officer, at ZK International, Inc. (NASDAQ: ZKIN), who talks about its xSigma blockchain technology. Mr. Lebed talks to the show’s viewers about ZKIN's wholly-owned xSigma Corporation which develops innovative software solutions that support the Company’s core operations while exploring new opportunities in smart contracts, distributed ledgers, supply chain management and blockchain architecture. TV interviews continue with Mr. James Sapirstein, Chairman & CEO of AzurRx BioPharma, Inc. (NASDAQ: AZRX), talking about AZRX’s biopharmaceutical products and therapies. He gives a comprehensive overview in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. And, provides insight on its FDA Phase 2 clinical trials on its lead therapeutic candidate is MS1819, a recombinant lipase for the treatment of exocrine pancreatic insufficiency (EPI) in patients with cystic fibrosis and chronic pancreatitis. “New To The Street” provides Mr. Roman Franklin, President and CEO at Simplicity Esports and Gaming, Inc. (OTCQB:WINR), the opportunity to talk to viewer about their established brand within the esports industry, operator of esports gaming centers, and owner of multiple esports teams. He continues the interview about the growth of the Company’s Esports Gaming Centers that provide the public an opportunity to experience and enjoy gaming and esports in a social setting, regardless of skill or experience. Another interview with Mr. Nile Tharandts Ortiz, the CEO and Co-founder of PayPolitan, walks our audiences through the evolution and development of PayPolitan blockchain technology. In particular he talks on “how” individual users can see all their crypto accounts on one screen and easily access to their current traditional bank accounts. He will share his industry view and comment on trends on people to transition to blockchain and trust the transfer of money. Finally, a long-term guest on “New To The Street”, welcomes back Mr. Allen Simon, CEO, Petproducts.com. Allen provides a wonder discussion about their premier online destination for pet supplies, treats, toys, food and much more, all delivered right to your door. And, he gives updates and trends in the pet industry. About American Premium Water Corporation (OTC:HIPH): American Premium Water Corporation (OTC:HIPH) is a diversified consumer products company focused on brands that utilize cutting edge bioscience technology. The Company is focused on harnessing the power of its proprietary Hydro Nano technology that utilizes CBD and other compounds to help increase the quality of life for its consumers – https://www.americanpremiumwater.com/. About WINNERS, INC. (OTC: WNRS): Winners, Inc. (WNRS:OTC), through its subsidiary VegasWINNERS, Inc., is engaged in the business of sports gambling research, data, advice, analysis and predictions utilizing all available media, advertising formats and its database of users. Revenues are expected to accelerate due to the explosion of sports handicapping arising from the 2018 Supreme Court decision that States have the right to approve sports gambling and the resulting State by State rapid approval of sports gambling. For more information, please visit Winners, Inc. website at https://vegaswinners.com/ and on social media at https://twitter.com/vegaswinnersinc. About InnerScope Hearing Technologies, Inc. (OTC:INND): InnerScope Hearing Technologies, Inc. is a manufacturer, distributor, and retailer of FDA-Registered Direct-to-Consumer ("DTC") App-Controlled Self-Adjusting Hearing Aids, App-Controlled Self-Adjusting Personal Sound Amplifiers Products, Doctor-Formulated Dietary Hearing & Tinnitus Supplements, and Assorted Ear & Hearing Health-Related Products with its mission is to improve the quality of life of the 70 million people in North America who suffer from hearing impairment and/or hearing-related issues. InnerScope with its Affordable App-Controlled Self-Adjusting Hearing Technology, combined with its innovative point of sale Hearing Screening Kiosks designed for consumers with mild-to-moderate hearing loss to purchase over-the-counter hearing aids without being seen by a hearing care professional- www.innd.com and www.NoHassleHearing.com About ZK International (NASDAQ:ZKIN): ZK International Inc’s xSigma ($SIG) blockchain R&D Lab has a mission to promote blockchain adoption by researching innovative use cases in decentralized finance, logistics, IoT, infrastructure and supply chain management. The Company and its management team explore ways to utilize decentralized technologies in various industries, creating value for both enterprise and consumer markets. It team of developers are formerly of Google, Facebook, Ripple Labs, 1inch and others – www.xsigma.com About AzurRx BioPharma (NASDAQ: AZRX): AzurRx BioPharma, Inc. (NASDAQ: AZRX) is a clinical stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The Company has a pipeline of three gut-restricted GI clinical programs. The lead therapeutic candidate is MS1819, a recombinant lipase for the treatment of exocrine pancreatic insufficiency (EPI) in patients with cystic fibrosis and chronic pancreatitis, currently in two Phase 2 clinical trials. AzurRx is launching two clinical programs using proprietary formulations of niclosamide, a pro-inflammatory pathway inhibitor; FW-420, for grade 1 Immune Checkpoint Inhibitor-associated colitis and diarrhea in oncology patients and FW-1022, for COVID-19 gastrointestinal infections – https://azurrx.com. About Simplicity Esports and Gaming, Inc. (OTCQB:WINR) Simplicity Esports and Gaming, Inc. is a North American esports organization which implemented a unique approach to ensure the ultimate fan friendly esports experience. The Company’s mission is to increase gamer and fan involvement at a grassroots level, and foster a sense of community as they compete with top-class talent. Simplicity Esports is represented by notable teams and player that compete on an international circuit. WINR staff and player are well known in the esports community whereas they leverage their notorieties, promoting and strengthening fan support and dedication to Simplicity Esports and Gaming, Inc. – https://ggsimplicity.com About Paypolitan: The Paypolitan platform will use blockchain technology, smart contracts and open banking APIs to provide a next-gen payment solution that meets the needs of modern payment systems for businesses and customers - https://paypolitan.io/#rec242830421 About Petproducts.com: PetProducts.com has been the leading global directory for all things pet. We are now giving consumers direct access to the products they need. We provide a one-stop shop for products, research, and reviews. PetProducts.com works diligently to serve pet lovers who deeply care about their animals - https://www.petproducts.com/ About FMW Media: FMW Media operates one of the longest-running U.S and International sponsored and Syndicated Nielsen Rated programming T.V. brands "New to the Street," and its blockchain show "Exploring The Block." Since 2009, these brands run biographical interview segment shows across major U.S. Television networks. The TV platforms reach over 540 million homes both in the US and international markets. FMW recently added Newsmax to its broadcasting platform with its first show broadcasted Sunday, December 27th. The NEWSMAX New to The Street show is syndicated on Sundays at 10 AM EST. FMW is also one of the nation's largest buyers of linear Television long and short form- https://www.newsmaxtv.com/Shows/New-to-the-Street https://www.newtothestreet.com/ Forward-Looking Statements Disclaimer: This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In some cases, you can identify forward-looking statements by the following words: "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "ongoing," "plan," "potential," "predict," "project," "should," "will," "would," or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. Forward-looking statements are not a guarantee of future performance or results, and will not necessarily be accurate indications of the times at, or by, which such performance or results achieved. This press release should be considered in light of all filings of the Company contained in the Edgar Archives of the Securities and Exchange Commission at www.sec.gov. FMW Media Contact: Bryan Johnson +1 (631) 766-7462 Bryan@NewToTheStreet.com

  • FMW Media’s “New To The Street” Syndicated TV Show Features AzurRx BioPharma, Inc.
    GlobeNewswire

    FMW Media’s “New To The Street” Syndicated TV Show Features AzurRx BioPharma, Inc.

    "New To The Street" business TV show will feature AzurRX BioPharma, Inc. (NASDAQ: AZRX) The televised interviews of with Mr. James Sapirstein, Chairman & CEO of AzurRx BioPharma, Inc., along with the “New To The Street’s” host Jane King, are to be broadcasted on syndicated Newsmax Television, Sunday mornings 10-11AM ET. Also, the TV interview is being broadcasted on FOX Business Network on Monday, May 17, 2021 at 10:30 PM PT. https://www.newsmaxtv.com/Shows/New-to-the-Street https://www.newtothestreet.com/ and http://www.foxbusiness.com NEW YORK, May 14, 2021 (GLOBE NEWSWIRE) -- FMW Media Corp. announces that its “New To The Street” business TV show will feature AzurRx BioPharma, Inc. (NASDAQ: AZRX) in a 3-part TV series featured across its entire syndicated linear television platform. The televised interviews of with Mr. James Sapirstein, Chairman & CEO of AzurRx BioPharma, Inc., along with the “New To The Street’s” host Jane King, are to be broadcasted on syndicated Newsmax Television, Sunday mornings 10-11AM ET. Also, the TV interview is being broadcasted on FOX Business Network on Monday, May 17, 2021 at 10:30 PM PT. Future filmed tapes and broadcasting on KRON-TV, RNN, Bloomberg TV and other stations “To Be Announced.” Mr. James Sapirstein, Chairman & CEO of AzurRx BioPharma (NASDAQ: AZRX) talks to the “New To The Street’s” TV audience about AZRX’s biopharmaceutical products and therapies. He gives a comprehensive overview in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. And, provides insight on its FDA Phase 2 clinical trials on its lead therapeutic candidate MS1819, a recombinant lipase for the treatment of exocrine pancreatic insufficiency (EPI) in patients with cystic fibrosis and chronic pancreatitis. James Sapirstein, CEO, AZRX states, “I am excited to be a guest on the ‘New To The Street’ TV program. The show has had a tremendous track record; I am happy to join the ranks. I look forward to educating viewers about AzurRx BioPharma - about our business, our biopharmaceutical products and therapies, and our future to grow the Company.” Vincent Caruso, CEO FMW Media Corp. and the Creator / Producer of “New To The Street” TV states, “I am excited to have AzurRx BioPharma, Inc. on the show for a 3-part series. AZRX’s biopharmaceutical products and therapies make them a great guest Company explaining their business to our syndicated TV audiences.” About AzurRx BioPharma (NASDAQ: AZRX): AzurRx BioPharma, Inc. (NASDAQ: AZRX) is a clinical stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The Company has a pipeline of three gut-restricted GI clinical programs. The lead therapeutic candidate is MS1819, a recombinant lipase for the treatment of exocrine pancreatic insufficiency (EPI) in patients with cystic fibrosis and chronic pancreatitis, currently in two Phase 2 clinical trials. AzurRx is launching two clinical programs using proprietary formulations of niclosamide, a pro-inflammatory pathway inhibitor; FW-420, for grade 1 Immune Checkpoint Inhibitor-associated colitis and diarrhea in oncology patients and FW-1022, for COVID-19 gastrointestinal infections – https://azurrx.com. About FMW Media: FMW Media operates one of the longest-running U.S and international sponsored and syndicated Nielsen Rated programming T.V. brands "New to the Street," and its blockchain show "Exploring The Block." Since 2009, these brands run biographical interview segment shows across major U.S. television networks. The TV platforms reach over 540 million homes both in the US and international markets. FMW recently added Newsmax to its broadcasting platform with its first show broadcasted Sunday, December 27th. The NEWSMAX New To The Street show is syndicated on Sundays at 10 AM EST. FMW is also one of the nation's largest buyers of linear television long and short form - https://www.newsmaxtv.com/Shows/New-to-the-Street and https://www.newtothestreet.com/ Forward-Looking Statements Disclaimer: This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In some cases, you can identify forward-looking statements by the following words: "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "ongoing," "plan," "potential," "predict," "project," "should," "will," "would," or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. Forward-looking statements are not a guarantee of future performance or results, and will not necessarily be accurate indications of the times at, or by, which such performance or results achieved. This press release should be considered in light of all filings of the Company contained in the Edgar Archives of the Securities and Exchange Commission at www.sec.gov. FMW Media Contact: Bryan Johnson +1 (631) 766-7462 Bryan@NewToTheStreet.com A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/6101c2d5-4b3e-4579-81a6-180539dfbce1

  • AzurRx BioPharma Stock Gains On Positive MS1819-PERT Combo Data In Pancreatic Insufficiency
    Benzinga

    AzurRx BioPharma Stock Gains On Positive MS1819-PERT Combo Data In Pancreatic Insufficiency

    AzurRx BioPharma Inc (NASDAQ: AZRX) announced positive interim data from the first 18 out of 20 patients from its Phase 2 trial. The study was evaluating MS1819 in combination with the current standard of care, porcine-derived pancreatic enzyme replacement therapy (PERT), for severe exocrine pancreatic insufficiency (EPI) in patients with cystic fibrosis (CF). The interim data revealed that the combination therapy led to clinically meaningful improvements in the primary efficacy endpoint, the Coefficient of Fat Absorption (CFA), with an average gain of 5.9 points from baseline, over the six-week trial. "It is also very encouraging to note that all the patients responded well and that many reported that they felt better overall when MS1819 was added to their daily dose of PERT", said Dr. James Pennington, Chief Medical Officer. Full topline results from all 20 patients enrolled in the trial are expected in the second quarter of 2021. MS1819 is a recombinant lipase enzyme supplied as an oral, non-systemic, biologic capsule derived from the Yarrowia lipolytica yeast lipase. It breaks up fat molecules in the digestive tract of EPI patients to be absorbed as nutrients. Price Action: AZRX shares are trading 8.9% higher at $0.79 during the premarket session on the last check Thursday. See more from BenzingaClick here for options trades from BenzingaPerkinElmer Expands Into Cell Biology With 0M Nexcelom Bioscience AcquisitionCuris Shares Drop On Safety Issues From Leukemia Study With CA-4948; Q1 Earnings Missing Estimates© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.